IMMU-22. EARLY RELEASE OF TYPE I INTERFERON DRIVES BRAIN CANCER IMMUNOGENICITY AND RESPONSE TO IMMUNOTHERAPY

BACKGROUND: Molecular drivers of cancer immunogenicity in brain tumors are still being unraveled. While BATF3 expression, STING, and interferon response factors (IRFs) are necessary for cancer immunogenicity, the presence of type I interferon (IFN-I) is contextual having been reported to elicit both...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Neuro Oncol
Main Authors: Wummer, Brandon, Qdaisat, Sadeem, Grippin, Adam, Karachi, Aida, Weidert, Frances, Huang, Jianping, Rahman, Maryam, Mitchell, Duane, Mendez-Gomez, Hector, Sayour, Elias
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2020
Teme:
Immunology
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651403/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.452
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki